Moderna announced European Medicines Agency’s Committee for Medicinal Products for human use recommends booster dose of Moderna’s COVID-19 vaccine in the European Union.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 µg dose level may be considered in people aged 18 years and older at least six months after completion of the primary series.
“This recommendation is supported by clinical evidence that a 50 µg booster dose induces a strong immune response against COVID-19. We thank the EMA and the CHMP for their review,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We believe that mRNA vaccines are well-positioned to adapt to the evolving epidemiology of SARS-CoV-2. We are grateful for the opportunity to provide individuals in the EU with another layer of protection.” (ILKHA)
LEGAL WARNING: All rights of the published news, photos and videos are reserved by İlke Haber Ajansı Basın Yayın San. Trade A.Ş. Under no circumstances can all or part of the news, photos and videos be used without a written contract or subscription.
Türkiye is facing a significant demographic shift, with its elderly population experiencing a rapid surge.
In a message emphasizing the spiritual and social dimensions of fasting, the Turkish Directorate of Religious Affairs delivered its Friday sermon this week, titled "Fasting: Health for the Body, Peace for the Heart."
The Turkish Statistical Institute (TSI) has published a detailed report highlighting key demographic and gender-related statistics in Türkiye, shedding light on various aspects of population dynamics and socio-economic indicators.
A new study published in The Lancet reveals a concerning trend: nine out of the ten countries with the highest obesity rates among adults are Pacific island nations.